Similar patient outcomes yet different hospital costs between flowable hemostatic agents

Abstract

Introduction:

SURGIFLO™ and FLOSEAL® are absorbable gelatin-based products that form hemostatic matrices. These products are indicated as adjuncts to hemostasis when control of bleeding by conventional surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. This study analyzed the effect of surgery time and the choice of product on cost to the hospital and patient outcomes.

Methods:

The data source was the Premier Hospital database from January 1, 2010–June 30, 2012. Eligible patients were ≥18 years of age with a spinal fusion or refusion surgery with either SURGIFLO™ (Ethicon Inc.) or FLOSEAL® (Baxter International Inc.). The hospital Charge Master was used to identify the amount of flowable product, whether it included Thrombin, and the cost. Multivariable models were performed on overall cost and likelihood of surgical complications. All models were adjusted for patient demographics and severity as well as hospital, and surgical characteristics.

Results:

A total of 24,882 patient records from 121 hospitals were analysed, which included 15,088 FLOSEAL® records and 9794 SURGIFLO™ records, with 1498 SURGIFLO™ with Thrombin patients. Little or no differences in surgical complications were found between surgeries with SURGIFLO™ vs surgery with FLOSEAL®. Regression models showed a reduction in cost of $65 associated with use of SURGIFLO™ with Thrombin and an additional $21 reduction in hospital cost for each additional hour of surgery. Modeling which accounts for hospital fixed effects suggest that, in addition to a gap of ∼$300 favoring SURGIFLO™ with Thrombin, every additional hour of surgery was associated with an additional reduction in hospital costs of ∼$26.

Conclusions:

While the choice of flowable product had no effect on clinical outcomes, use of SURGIFLO™ was associated with hospital cost savings for flowable product. These savings increased with the length of surgery, even when controlling for the amount of flowable product (mL) used.

Keywords::

• SURGIFLO
• FLOSEAL
• Absorbable gelatins
• Flowable hemostatic agents
• Hospital cost savings
• Patient outcomes

Transparency

Declaration of funding

This study was funded by Ethicon, Inc. The publication of study results was not contingent on the sponsor’s approval or censorship of the manuscript.

Declaration of financial/other relationships

CG is an employee and GD is an academic affiliate of CTI Clinical Trial and Consulting Services, Inc., which is a paid consultant to Ethicon, Inc. SL, RK, and SR are employees of Ethicon, Inc., the study sponsor. JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.